// App-Quantinova.ai

: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial

Researchers

Presenter

  • BERNARD CHARBONNEL

Principal Investigators

  • VANITA R. ARODA

  • JUKKA WESTERBACKA

  • FELIPE LAUAND SR

  • EMMANUELLE BOELLE

  • ALICE Y. CHENG

  • JULIO ROSENSTOCK

Medical Centers

  • N/A

Locations

  • France

  • United States

  • Canada

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • AT-rich interactive domain 3A

  • Hemoglobin A1c

  • Insulin

  • Body mass index

Drug/Treatment

  • Insulin glargine

  • Insulin degludec

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved